IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9988376 B1

PDFFull Text
Date of Patent:
Jun. 05, 2018

Filed:

Jul. 01, 2014

Benzothiophene derivatives as estrogen receptor inhibitors

Applicant:

Glaxosmithkline Intellectual Property Development Limited, Brentford, Middlesex, GB;

Inventors:

Sebastien Andre Campos, Stevenage, GB;

John David Harling, Stevenage, GB;

Afjal Hussain Miah, Stevenage, GB;

Ian Edward David Smith, Stevenage, GB;

Assignee:

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, Brentford, Middlesex, GB;

Attorneys:

Bryan D. Zerhusen

Locke Lord LLP

Primary Examiner:

Craig D Ricci

Assistant Examiner:

Janet L Coppins

Int. Cl.
CPC ...
C07D 417/14 (2006.01); C07D 413/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/435 (2006.01); A61K 31/496 (2006.01); A61K 38/05 (2006.01); A61K 45/06 (2006.01); C07D 471/10 (2006.01); C07K 5/062 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/435 (2013.01); A61K 31/496 (2013.01); A61K 38/05 (2013.01); A61K 45/06 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 471/10 (2013.01); C07K 5/06052 (2013.01);
Abstract

A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor.

Find Patent Forward Citations

Loading…